Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The lesson's learned in this situation are the consequences of a. ....

Gave you a thumbs up. Good points. But I do not think any institutional investor is going to seriously look at PTSC until we are at least $10/share and on a major exchange. Also if our core business is IP licensing that too is going to prevent institutional investors from "loading up" on PTSC shares. That business model simply does not appeal to them. Goerner's efforts to build a second revenue stream with these mergers and acquisitions, funded with IP lecenscing revenues, are far more importent. But what do I know, I thought the Mets were going to win it all.

Share
New Message
Please login to post a reply